Učitavanje...
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treate...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3359733/ https://ncbi.nlm.nih.gov/pubmed/22371887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-405456 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|